U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    33,795.34
    +1,231.32 (+3.78%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Merck's Next-Gen Pneumococcal Conjugate Vaccine Shows Efficacy In Pediatric Trials

·1 min read
  • Merck & Co Inc's (NYSE: MRK) investigational 15-valent pneumococcal conjugate vaccine, V114, has met its primary immunogenicity and safety endpoints in two Phase 3 pediatric programs.

  • Full results from PNEU-DIRECTION and PNEU-PLAN will be presented at a future scientific congress.

  • In the PNEU-DIRECTION (V114-027) interchangeability study in healthy infants 42-90 days of age, immune responses in those who received a four-dose series of currently available 13-valent pneumococcal conjugate vaccine (PCV13), and those who received a mixed dose schedule of PCV13 followed by V114, were generally comparable.

  • In the PNEU-PLAN (V114-024) catch-up study, immune responses were generally comparable to PCV13 when V114 was used as a catch-up regimen in healthy children seven months to 17 years who were either pneumococcal vaccine-naïve or who previously received a partial or full regimen of pediatric PCV.

  • V114 showed immunogenicity against two additional serotypes, 22F and 33F, as well.

  • In each study, V114 was generally well-tolerated, with a safety profile comparable to PCV13.

  • V114 is Merck's investigational 15-valent pneumococcal conjugate vaccine in Phase 3 development.

  • Price Action: MRK shares are down 0.44% at $79.01 in the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.